SION
Sionna Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.01
+3.08%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -17.0%
- EBIT
- -24.9%
- EPS
- -26.5%
- Free cash flow
- -53.1%
- Operating cash flow
- -53.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +4.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -22.3%
- EBIT
- -26.1%
- Net income
- -22.0%
- EPS
- -34.3%
- Free cash flow
- -26.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026